爱尔兰临床肿瘤学分子诊断概述。

HRB open research Pub Date : 2025-06-09 eCollection Date: 2024-01-01 DOI:10.12688/hrbopenres.13822.2
Tyler Medina, Seán O Hynes, Maeve Lowery, Patrick Gillespie, Walter Kolch, Cathal Seoighe
{"title":"爱尔兰临床肿瘤学分子诊断概述。","authors":"Tyler Medina, Seán O Hynes, Maeve Lowery, Patrick Gillespie, Walter Kolch, Cathal Seoighe","doi":"10.12688/hrbopenres.13822.2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Molecular diagnostics are critical for informing cancer patient care. In Ireland, the National Cancer Control Programme (NCCP) develops cancer therapy regimens, which include relevant information on molecular indications. Here, we present a collated overview of the current molecular indications of all NCCP systemic anti-cancer therapy regimens and the funding statuses of their associated drugs. Furthermore, we also provide estimates for the scale of required molecular testing in cancer therapy and for the clinical genetic sequencing capacity of Ireland, and provide a summary of current cancer clinical trials in Ireland which have molecular components.</p><p><strong>Methods: </strong>Through a combination of web scraping, keyword search, and manual review, we performed a full review of all 856 indications included in the 533 therapy regimens published to date by the NCCP to identify therapy indications with explicit molecular criteria. For all cancer types identified in these indications, we obtained incidence rates in Ireland from National Cancer Registry Ireland to predict the number of patients yearly who stand to benefit from a molecular test. We then applied molecular subtype rates from published literature to estimate the number of patients who would then qualify for a relevant molecularly guided therapy.</p><p><strong>Results: </strong>We identified 246 indications for 175 NCCP therapy regimens that include molecular criteria. These 246 molecular indications encompassed 101 genetic criteria, 161 cellular biomarker criteria, 63 molecularly informed drugs, and over 20 cancer types. We estimated that up to approximately 55% of cancer patients in Ireland could qualify for a molecular test and that the majority of tested patients would qualify for a treatment informed by a molecular test.</p><p><strong>Conclusions: </strong>As personalised cancer medicine continues to develop in Ireland, this study will provide a baseline understanding of current practices. We anticipate that work such as this will help to inform planning in the healthcare system.</p>","PeriodicalId":73254,"journal":{"name":"HRB open research","volume":"7 ","pages":"16"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12272048/pdf/","citationCount":"0","resultStr":"{\"title\":\"Overview of Molecular Diagnostics in Irish Clinical Oncology.\",\"authors\":\"Tyler Medina, Seán O Hynes, Maeve Lowery, Patrick Gillespie, Walter Kolch, Cathal Seoighe\",\"doi\":\"10.12688/hrbopenres.13822.2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Molecular diagnostics are critical for informing cancer patient care. In Ireland, the National Cancer Control Programme (NCCP) develops cancer therapy regimens, which include relevant information on molecular indications. Here, we present a collated overview of the current molecular indications of all NCCP systemic anti-cancer therapy regimens and the funding statuses of their associated drugs. Furthermore, we also provide estimates for the scale of required molecular testing in cancer therapy and for the clinical genetic sequencing capacity of Ireland, and provide a summary of current cancer clinical trials in Ireland which have molecular components.</p><p><strong>Methods: </strong>Through a combination of web scraping, keyword search, and manual review, we performed a full review of all 856 indications included in the 533 therapy regimens published to date by the NCCP to identify therapy indications with explicit molecular criteria. For all cancer types identified in these indications, we obtained incidence rates in Ireland from National Cancer Registry Ireland to predict the number of patients yearly who stand to benefit from a molecular test. We then applied molecular subtype rates from published literature to estimate the number of patients who would then qualify for a relevant molecularly guided therapy.</p><p><strong>Results: </strong>We identified 246 indications for 175 NCCP therapy regimens that include molecular criteria. These 246 molecular indications encompassed 101 genetic criteria, 161 cellular biomarker criteria, 63 molecularly informed drugs, and over 20 cancer types. We estimated that up to approximately 55% of cancer patients in Ireland could qualify for a molecular test and that the majority of tested patients would qualify for a treatment informed by a molecular test.</p><p><strong>Conclusions: </strong>As personalised cancer medicine continues to develop in Ireland, this study will provide a baseline understanding of current practices. We anticipate that work such as this will help to inform planning in the healthcare system.</p>\",\"PeriodicalId\":73254,\"journal\":{\"name\":\"HRB open research\",\"volume\":\"7 \",\"pages\":\"16\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-06-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12272048/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"HRB open research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12688/hrbopenres.13822.2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"HRB open research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12688/hrbopenres.13822.2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:分子诊断对癌症患者的护理至关重要。在爱尔兰,国家癌症控制规划(NCCP)制定了癌症治疗方案,其中包括分子适应症的相关信息。在这里,我们对目前所有NCCP系统性抗癌治疗方案的分子适应症及其相关药物的资助状况进行了整理概述。此外,我们还提供了对癌症治疗所需的分子测试规模和爱尔兰临床基因测序能力的估计,并提供了爱尔兰目前具有分子成分的癌症临床试验的总结。方法:通过网络抓取、关键词搜索和人工审查的结合,我们对NCCP迄今为止公布的533个治疗方案中的所有856个适应症进行了全面审查,以确定具有明确分子标准的治疗适应症。对于在这些适应症中确定的所有癌症类型,我们从爱尔兰国家癌症登记处获得了爱尔兰的发病率,以预测每年从分子测试中受益的患者数量。然后,我们应用已发表文献中的分子亚型率来估计有资格接受相关分子引导治疗的患者数量。结果:我们确定了175种NCCP治疗方案的246种适应症,包括分子标准。这246个分子适应症包括101个遗传标准、161个细胞生物标志物标准、63个分子知情药物和20多种癌症类型。我们估计,爱尔兰大约55%的癌症患者有资格进行分子检测,大多数接受检测的患者有资格接受分子检测提供的治疗。结论:随着个体化癌症医学在爱尔兰的不断发展,这项研究将为当前的实践提供一个基本的理解。我们预计,这样的工作将有助于告知计划在医疗保健系统。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Overview of Molecular Diagnostics in Irish Clinical Oncology.

Overview of Molecular Diagnostics in Irish Clinical Oncology.

Overview of Molecular Diagnostics in Irish Clinical Oncology.

Background: Molecular diagnostics are critical for informing cancer patient care. In Ireland, the National Cancer Control Programme (NCCP) develops cancer therapy regimens, which include relevant information on molecular indications. Here, we present a collated overview of the current molecular indications of all NCCP systemic anti-cancer therapy regimens and the funding statuses of their associated drugs. Furthermore, we also provide estimates for the scale of required molecular testing in cancer therapy and for the clinical genetic sequencing capacity of Ireland, and provide a summary of current cancer clinical trials in Ireland which have molecular components.

Methods: Through a combination of web scraping, keyword search, and manual review, we performed a full review of all 856 indications included in the 533 therapy regimens published to date by the NCCP to identify therapy indications with explicit molecular criteria. For all cancer types identified in these indications, we obtained incidence rates in Ireland from National Cancer Registry Ireland to predict the number of patients yearly who stand to benefit from a molecular test. We then applied molecular subtype rates from published literature to estimate the number of patients who would then qualify for a relevant molecularly guided therapy.

Results: We identified 246 indications for 175 NCCP therapy regimens that include molecular criteria. These 246 molecular indications encompassed 101 genetic criteria, 161 cellular biomarker criteria, 63 molecularly informed drugs, and over 20 cancer types. We estimated that up to approximately 55% of cancer patients in Ireland could qualify for a molecular test and that the majority of tested patients would qualify for a treatment informed by a molecular test.

Conclusions: As personalised cancer medicine continues to develop in Ireland, this study will provide a baseline understanding of current practices. We anticipate that work such as this will help to inform planning in the healthcare system.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.40
自引率
0.00%
发文量
0
审稿时长
6 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信